標(biāo)題: Titlebook: Drug and Biological Development; From Molecule to Pro Ronald P. Evens Textbook 2007 Springer-Verlag US 2007 Biological.Development.Drugs.Ev [打印本頁(yè)] 作者: 游牧 時(shí)間: 2025-3-21 17:08
書(shū)目名稱Drug and Biological Development影響因子(影響力)
書(shū)目名稱Drug and Biological Development影響因子(影響力)學(xué)科排名
書(shū)目名稱Drug and Biological Development網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Drug and Biological Development網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Drug and Biological Development被引頻次
書(shū)目名稱Drug and Biological Development被引頻次學(xué)科排名
書(shū)目名稱Drug and Biological Development年度引用
書(shū)目名稱Drug and Biological Development年度引用學(xué)科排名
書(shū)目名稱Drug and Biological Development讀者反饋
書(shū)目名稱Drug and Biological Development讀者反饋學(xué)科排名
作者: choleretic 時(shí)間: 2025-3-21 20:55
Building a Workflow with Visual Studio 2005osine kinase, and be used only when the receptor system goes awry. Knowledge of the discovery and early development process creates a basis for understanding how potential new therapeutics advance from the research laboratory to the clinic and some of the issues involved.作者: cluster 時(shí)間: 2025-3-22 00:28
unch, and through the industry are also addressed throughout the chapters. This life cycle management for the new researcher in academia or book shares how this success and the challenges are acc- industry. The978-0-387-69094-0作者: Irritate 時(shí)間: 2025-3-22 06:35
R&D Planning and Governance,periences and expectations, they each believe to be holding a different animal with different possible benefits and risks in reaching their destination. Someone or some group must be able to step back and see the whole animal, as well as its parts, to coordinate the individual players, help make the作者: Coronary-Spasm 時(shí)間: 2025-3-22 09:20 作者: Invertebrate 時(shí)間: 2025-3-22 16:21 作者: Invertebrate 時(shí)間: 2025-3-22 19:30 作者: 頂點(diǎn) 時(shí)間: 2025-3-22 21:53 作者: abysmal 時(shí)間: 2025-3-23 02:49
Health Care and Industry Overview and Challenges, the organization of a pharmaceutical company, and drug and biological product development challenges. Thus, a framework is provided for the following 11 chapters that will discuss all the people, processes, systems, and outcomes for drug and biological development applicable in the United States and in Europe as well.作者: Essential 時(shí)間: 2025-3-23 07:21 作者: 仔細(xì)閱讀 時(shí)間: 2025-3-23 12:22
very through a product’s life cycle.The unique features of tRonald P. Evens Editors and Authors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Editor . . . . . . . . . . . . . . . . . . . . . .作者: mastoid-bone 時(shí)間: 2025-3-23 15:46 作者: Tinea-Capitis 時(shí)間: 2025-3-23 20:24 作者: ADORE 時(shí)間: 2025-3-24 01:05
R&D Outcomes,ctivity, meet the needs of the public and health care community for the best products used optimally, meet the needs of the shareholders, and sustain the company’s research edge against the competition.作者: 迅速飛過(guò) 時(shí)間: 2025-3-24 06:18 作者: 不能仁慈 時(shí)間: 2025-3-24 10:31 作者: 提升 時(shí)間: 2025-3-24 10:44
Types of Clinical Studies,nd differing requirements for patient types, goals, inclusion/exclusion criteria, design features, and expected outcomes. Combined, they build the patient care database for safety and efficacy that hopefully will lead to product approval.作者: Decrepit 時(shí)間: 2025-3-24 16:26 作者: Ibd810 時(shí)間: 2025-3-24 20:10 作者: 失望昨天 時(shí)間: 2025-3-25 03:07
Special Considerations in Research,Cardiovascular research is addressed in this chapter as a special therapeutics area, especially given its different and unique study needs and designs, the many indications for use of the products, the extensive pharmaceutical markets in patient numbers and sales potential, and the many products that exist and are investigational agents.作者: euphoria 時(shí)間: 2025-3-25 04:14
Laws and Regulations: The Discipline of Regulatory Affairs,ies and competitive landscape, protection of the intellectual property surrounding a drug product, and the compliance efforts of a pharmaceutical company. It requires knowledge and, most importantly, interpretation of the most current requirements of regulatory authorities around the world.作者: MOTTO 時(shí)間: 2025-3-25 09:06
Formulation and Manufacturing,y result in a patient taking a tablet, inhaling a powder, or taking some other formulation of a drug product to alleviate or cure a malady. This chapter focuses on the steps entailed to create the actual product, the formulation, which a patient takes for his or her malady, from initial concept through commercial sale.作者: Gesture 時(shí)間: 2025-3-25 12:28 作者: nutrients 時(shí)間: 2025-3-25 16:06 作者: progestogen 時(shí)間: 2025-3-25 19:59
https://doi.org/10.1007/978-0-387-69094-0Biological; Development; Drugs; Evens; Molecule; infectious disease; metabolism作者: 共同時(shí)代 時(shí)間: 2025-3-26 03:01
Springer-Verlag US 2007作者: membrane 時(shí)間: 2025-3-26 06:48
Building a Workflow with Visual Studio 2005research experiences (basic and clinical research with many disciplines, technologies, and processes), personnel/professional affairs, business and marketing practices, public relations, legal and regulatory issues, and global business, cultural, and medical factors. This chapter is intended to prov作者: 類人猿 時(shí)間: 2025-3-26 11:13 作者: BALE 時(shí)間: 2025-3-26 14:37
Building a Workflow with Visual Studio 2005nology companies. New products often are prescribed preferentially by physicians for the mitigation of disease and improvement of patient care because of their novel features over existing treatments. These new products will be the primary driver of innovations in health care, research advances, pro作者: 稱贊 時(shí)間: 2025-3-26 17:22
Building a Workflow with Visual Studio 2005, it starts in the minds of scientists with a scientific innovation or idea for creating a new therapeutic molecule that may be a biological or drug. This research is performed through carefully done studies, either with the physiology of humans or other species, disease models, or some core structu作者: Foolproof 時(shí)間: 2025-3-26 21:09
Building a Workflow with Visual Studio 2005ogic product for use in humans, a series of clinical studies must be performed. These clinical studies exist in four phases. Each phase has specific and differing requirements for patient types, goals, inclusion/exclusion criteria, design features, and expected outcomes. Combined, they build the pat作者: acheon 時(shí)間: 2025-3-27 02:49
Magazine: My, What a Classy ent among multiple candidates and how the compound should be dosed. As a discipline, pharmacokinetics (PK) is the study of what the body does to the drug, that is, the absorption, distribution, metabolism, and excretion (ADME) of the drug, whereas pharmacodynamics (PD) seeks to define what the drug 作者: REIGN 時(shí)間: 2025-3-27 07:59 作者: 下垂 時(shí)間: 2025-3-27 11:40
Creating Dynamic Interfaces Using JavaScriptnd non-U.S. trials as well. Although the focus of this chapter is on the development of new drugs (including biologics), many of the principles are also applicable to medical device development. Note, however, that while similarities in principle exist, device development is governed by separate U.S作者: AFFIX 時(shí)間: 2025-3-27 16:39
Magazine: My, What a Classy y result in a patient taking a tablet, inhaling a powder, or taking some other formulation of a drug product to alleviate or cure a malady. This chapter focuses on the steps entailed to create the actual product, the formulation, which a patient takes for his or her malady, from initial concept thro作者: Permanent 時(shí)間: 2025-3-27 17:54
Magazine: My, What a Classy ies and competitive landscape, protection of the intellectual property surrounding a drug product, and the compliance efforts of a pharmaceutical company. It requires knowledge and, most importantly, interpretation of the most current requirements of regulatory authorities around the world.作者: 控制 時(shí)間: 2025-3-28 01:03 作者: reperfusion 時(shí)間: 2025-3-28 04:05 作者: 夜晚 時(shí)間: 2025-3-28 10:19
R&D Planning and Governance,dership, appropriate patients, experienced investigators, a good dose of common sense, a vision of the future, and some luck to develop significant new products. Many companies may possess these attributes; however, how well companies can pull all these manifold, often disparate, and sometimes confl作者: Acumen 時(shí)間: 2025-3-28 14:17
R&D Outcomes,nology companies. New products often are prescribed preferentially by physicians for the mitigation of disease and improvement of patient care because of their novel features over existing treatments. These new products will be the primary driver of innovations in health care, research advances, pro作者: 審問(wèn),審訊 時(shí)間: 2025-3-28 15:27 作者: 反復(fù)拉緊 時(shí)間: 2025-3-28 20:13 作者: Accolade 時(shí)間: 2025-3-29 00:54 作者: 小爭(zhēng)吵 時(shí)間: 2025-3-29 06:47
Laws and Regulations: The Discipline of Regulatory Affairs,ies and competitive landscape, protection of the intellectual property surrounding a drug product, and the compliance efforts of a pharmaceutical company. It requires knowledge and, most importantly, interpretation of the most current requirements of regulatory authorities around the world.作者: syring 時(shí)間: 2025-3-29 09:03 作者: 注視 時(shí)間: 2025-3-29 15:12
Formulation and Manufacturing,y result in a patient taking a tablet, inhaling a powder, or taking some other formulation of a drug product to alleviate or cure a malady. This chapter focuses on the steps entailed to create the actual product, the formulation, which a patient takes for his or her malady, from initial concept thro作者: sigmoid-colon 時(shí)間: 2025-3-29 17:23
10樓作者: 絕種 時(shí)間: 2025-3-29 20:40
10樓作者: 效果 時(shí)間: 2025-3-30 02:23
10樓
